Table 1 Clinical characteristics of β-amyloid positivity converters and non-converters
From: Predicting conversion of brain β-amyloid positivity in amyloid-negative individuals
ADNI dataset | SMC dataset | p-value† | |||||||
|---|---|---|---|---|---|---|---|---|---|
Total | Converter | Nonconverter | p-value | Total | Converter | Nonconverter | p-value | ||
Subjects, N (%) | 229 (100.0) | 53 (23.1) | 176 (75.1) | - | 40 (100.0) | 10 (25.0) | 30 (75.0) | - | - |
Follow-up duration (years) | 7.1 (1.7) | 5.7 (2.2) | 7.5 (1.3) | <0.001* | 6.1 (2.0) | 3.9 (1.2) | 6.7 (1.6) | <0.001* | <0.001* |
Age, mean years (SD) | 71.7 (7.3) | 72.9 (6.8) | 71.3 (7.5) | 0.163 | 70.1 (7.7) | 75.0 (8.1) | 69.5 (7.3) | 0.050 | 0.498 |
Female, N (%) | 108 (47.2) | 23 (43.4) | 85 (48.3) | 0.639 | 28 (68.3) | 7 (70.0) | 20 (67.7) | 1.000 | 0.028* |
APOE ε4 carriers, N (%) | 54 (23.6) | 20 (37.7) | 34 (19.3) | 0.010* | 5 (12.5) | 3 (30.0) | 2 (6.7) | 0.168 | 0.175 |
Education, years (SD) | 16.5 (2.7) | 16.6 (2.3) | 16.5 (2.8) | 0.813 | 9.0 (4.6) | 11.2 (4.2) | 8.3 (4.6) | 0.087 | <0.001* |
Family history, N (%) | 124 (54.1) | 31 (58.4) | 93 (52.8) | 0.571 | 10 (24.4) | 4 (40.0) | 6 (19.4) | 0.369 | 0.001* |
Amyloid tracer uptakea, mean (SD) | 1.017 (0.054) | 1.058 (0.039) | 1.005 (0.052) | <0.001* | 3.377 (7.325) | 12.052 (5.492) | 0.088 (4.754) | <0.001* | - |